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ABSTRACT 
Butea Monosperma is an Indian traditional plant used in treating diabetes. Butea Monosperma posses strong antioxidant, 
α-glucosidase inhibitory activity. And the aqueous extract of the flower also have the chemical constituents which are responsible for 
having free radical scavenging nature. The Phytochemical screening of the aqueous extract of flower of Butea Monosperma showed 
the positive results for Flavonoids, Glycosides, Carbohydrates and Amino Acids. From The Phytochemical study we found that the 
extract has the antioxidant properties. By this Result we extended our work by administering in diabetes induced SD Rats to check 
whether it has any antidiabetic activity or not. So, after treating the diabetic rats for 14days with our extract we found that the blood 
glucose levels got decreased when we compared it with the first day of glucose levels. Hence, we confirmed that the aqueous extract of 
the flower of Butea Monosperma has the antidiabetic activity. 
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INTRODUCTION 
Diabetes mellitus is reaching as epidemic proportion 
across the globe, a metabolic disorder characterize by 
hyperglycemia resulting from defect in insulin secretion, 
insulin action or both (ADA, 2009). Currently, there are 40 
million people with diabetes in India estimated to rise to 
almost 70 million by 2025 (IDF, 2006). It is estimated that 25% 
of the world population isaffected by this disease. 
Hyperglycemia is the most important factor in the onset and 
progress of diabetic complications mainly by producing 
oxidative stress (Giugliano et al.,1996). Altered cellular 
metabolism caused by hyperglycemia has been suggested to 
play an important role in increasing the risk of cardiovascular, 
renal, ophthalmic and neurological complications of diabetes 
mellitus (Brownlee and Cerami, 1981).Diabetes is a disease 
condition in which blood glucose level concentrations elevated 
i.e hyperglycemia  due to loss of insulin secretion by pancreatic 
β-cells called type-I diabetes or loss of insulin responsiveness 
in targeted tissues referred as type-II diabetesor both 
(Schwarz, P.E et al., 2009). It is one of the most common 
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metabolic syndromes, since there are 200 million diabetic 
individuals in the world it is needed to understand the etiology 
and factors influencing onset of the disease (WHO, 1985). 
Pathogenic factors that are involved in the development of 
disease are auto-immune destruction of the β-cells of pancreas 
with consequent insulin deficiency to abnormalities results in 
insulin resistance. Deficient action of insulin on target tissues 
and hyperglycemia are the basis of the abnormalities in fat, 
carbohydrate, and protein metabolism, causing diabetic 
characteristic clinical features, increased risk of cardiovascular 
disease, micro and macro vascular complications (WHO, 1985). 
Diabetes mellitus is a metabolic disorder characterized by 
hyperglycemia, Polyuria, glycosuria. Reasons for this rise 
include sedentary lifestyle, obesity, consumption ofenergy rich 
diet, higher life span. It is important to remember that diabetes 
can occur without anysymptoms. Diabetes is a complex disease 
and not everyone has thesame symptoms. In general, excess 
sugar in blood is removed bythe kidneys, using up large 
amounts of water in the process: soone of the most common 
symptoms is that you may pass moreurine and drink a lot more 
in order to compensate for the loss of liquid. 
Insulin is the principal signal that controls the 
conversion of glucose to glycogen for internal storage in liver 
and muscle cells. Reduction in the insulin release from the beta 
cells and reverse conversion of glycogen to glucose when fall in 
glucose level results in lowering glucose levels that is 
controlled by the glucagon hormone which counter acts the 
action of insulin (Rama Rao Naidu B.V.A, 2005). Glucose that is 
produced from the internal liver cells stores as glycogen which 
re-enters the blood stream; when muscle cells lack the 
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necessary export mechanism. Normally when the insulin levels 
are low liver cells do this which normally correlates with low 
levels of blood glucose (Yoganarasimhan, S.N, 2005). 
Higher insulin levels increase in anabolic process, 
such as protein synthesis, fat storage, growth and duplication. 
Presence or lack of insulin is the principal signal in converting 
many of the bidirectional process of metabolism i.e from 
catabolism to anabolism and vice versa. Particularly low insulin 
level is the trigger for entering or leaving ketosis which is the 
fat burning metabolic phase. If there is shortage of insulin 
availability, cells respond poorly to the effects of insulin called 
insulin sensitivity or resistance. Glucose will not have its usual 
effect when there is defect in insulin, so there will be no proper 
absorption by the body cells that require it, nor stored 
appropriately in the liver and muscles. The net effect is 
persistent high glucose levels in blood, other metabolic 
derangements, such as acidosis and poor protein synthesis. 
MATERIALS & METHODS 
Experimental Animals: 
Healthy Wister rats, weighing between 150-200gm of 
either sex are used for the study. Animals procured from the 
animal house of Sainath Agencies and were housed 
individually in clean polypropylene cages in air-conditioned 
room where the temperature was 22±2oC with 50%±10% 
relative moisture with a 12 h light and dark cycle all over the 
study, animals were maintained at normal laboratory 
circumstances and were given commercial laboratory animal 
feed and water with libitum. Prior to conducting experiments, 
ethical permission was taken from Institute’s Animal Ethics 
Committee (IAEC) of CPCSEA Reg.no.930/PO/a/2018/CPCSEA. 
Chemicals: 
Alloxan (Sigma Pvt. Ltd. India). Glibenclamide 
(10mg/kg) reagent kits for alkaline SGOT, SGPT, TG’s, (EX-cel 
life science Pvt.Ltd), Sodium citrate, HCl, CMC and all other 
chemicals worn in the study are of analytical grades procured 
from respective manufacturers. 
Plant material collection and authentication: 
The fresh whole plants of Butea Monospermawere 
obtained from Boduppal, Hyderabad, Telangana in the month 
of February and they were authentified by Prof. Dr. H 
Ramakrishna, Botanist, Osmania University. 
Extraction procedure: 
The whole plants were shade dried, powdered, and 
sieved (mesh no. 40) to get coarse powder. Then this 
powdered coarse plant material was packed into soxhelet 
apparatus subjected to soxhlation using aqueous as solvent for 
72 hours at a temperature of 40°c. After filtration, it was 
evaporated using water bath at a temperature not exceeding 
40°c until the crude extract was obtained as a semi solid and 
air dried to get solid mass. 
Selection of dose: 
Plant extract was prepared according to ED50 of 
individual herbs. ED50 of individual plants was found to be as, 
Butea Monosperma (200 mg/kg). Plant extractat a dose of 
200mg/kg and 400mg/kg were used for the present study 
according to ED50 values from previous studies. 
Experimental Design: 
The healthy female animals were randomly selected 
into five groups, each group containing 6 animals were treated 
for 28 days, as given in following treatment schedule Aqueous 
extract of Butea Monosperma was freshly suspended in 
distilled water and administered to animals by oral feeding 
needle. The standard drug Glibenclamide (5mg/kg, p.o) was 
prepared by suspending in a 1% CMC using mortar and pestle, 
made as a suspension and administered immediately. 
 
Table No. 1: Treatment schedule for assessing anti antidiabetic activity of Aqueous Extract of Butea Monosperma 
S.No GROUPS TREATMENT PURPOSE 
I Normal Normal saline Serves as normal 
II Negative control  Alloxan(40mg/kg i.p) Serves as disease control 
III Standard Alloxan + Glibenclamide(5mg/kg p.o) To study the effect of  Glibenclamide 
in disease condition 
IV Test-I Alloxan + Low dose of Plant extract To study the  effect of Butea Monosperma at low 
dose  in disease condition 
V Test-II Alloxan + High dose of Plant extract To study the  effect of Butea Monosperma at high 
dose in disease condition 
 
Acute toxicity studies: 
Acute toxicity studies were performed to test the 
lethal or toxic dose of the test drug on animals to avoid any 
complications while administering the plant extract. The acute 
oral toxicity study was carried out according to the OECD 423 
guidelines protocol. In this study female rats (n=3) weighing 
about 180-220gm were used in the testing dose of 2000mg/kg 
body weight. Then they were observed for signs of toxicity and 
mortality for 14 days from the initial day of dosing. 
It was observed that there were no signs of toxicity 
and mortality for 14 days at a testing dose of 2000mg/kg body 
weight. Therefore one-tenth of the maximum no mortality dose 
of extract were selected low dose 200mg/kg and high dose 
400mg/kg. 
RESULTS& DISCUSSION 
In-Vivo studies: 
The in-vivo testing was performed on albino Wistar 
rats of either sex (150-220gm) obtained from Sai nath agencies 
animal house  which were housed under standard laboratory 
conditions and fed with commercial rat feed (Lipton India Ltd., 
Mumbai, India) and boiled water, ad libitum. All the animal 
experiments were carried out according to NIH guidelines, 
after getting the approval from the Institute’s Animal Ethics 
Committee (IAEC) of CPCSEA Reg.no.930/PO/a/2018/CPCSEA. 
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guidelines protocol. In this study female rats (n=3) weighing 
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Table No. 2: Results of Acute toxicity studies 
S.no Initial weight Final weight Signs of toxicity Mortality 
Behavioral Somatic Neurological 
1. 185 210gm No signs No signs No signs Nil 
2. 190 204gm No signs No signs No signs Nil 
3. 199 214gm No signs No signs No signs Nil 
 
Oral Glucose Tolerance Test (OGTT): 
OGTT was carried out to confirm the induction of 
type 2 diabetes. Rats, after 12 hr of fasting were given orally, a 
glucose challenge of 2g/Kg body weight. Blood glucose was 
determined by the above mentioned method at 0, 30, 60,120 
and 180 min after glucose challenge. A plot of Blood glucose 
level versus time obtained was analyzed for impairment in 
glucose tolerance, to confirm the induction/extent of diabetes. 
 
Table No. 3: Results of Blood Glucose Levels 7th Day 
CONDITION 0hr 30min 1hr 2hr 4hr 
Control 70±2.1 73±2.22 70±1.9 71±1.1 72±2.29 
Negative control 298±2.5 291±3.1 317±2.6 286±1.5 260±2.53 
Standard 274±1.3 289±2.3 298±1.6 265±2.1 240±2.51 
Low dose 262±1.2 270±2.9 281±2.29 246±2.9*** 228±1.78** 
High dose 276±1.9 286±2.4 294±3.4 270±3.03 260±2.23 
* Values are significant as the P values are <0.0001, were determined by using one-way ANOVA test with DUNNET’S multiple comparison test. 
 
 
Fig. 1: Results of Blood Glucose Levels 7th Day 
Table No. 4: Results of Blood Glucose Levels 14th Day 
CONDITION 0hr 30min 1hr 2hr 4hr 
Control 71±1.87 72±4.1 70±1.2 71±1.11 72±1.01 
Negative control 270±2.76 280±3.22 292±2.1 282±2.59 269±2.09 
Standard 268±1.9 270±3.67 286±1.89 241±1.84*** 212±1.47** 
Low dose 246±3.2 260±1.98 270±3.1 232±1.91 226±1.83 
High dose 226±3.2 240±1.98 260±3.1 252±1.91 236±1.83 
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Fig. 2: Results of Blood Glucose Levels 14th Day 
Values are expressed in mean +SEM, (n=6), when compared with control, *P<0.01, **P<0.001, one-way ANOVA followed by Dunnet’s t – Test. 
ALLOXAN (40mg/kg) was injected to all groups except control. Alloxan induced diabetic group vs normal group, bExtract treated group vs 
ALLOXAN induced diabetic group. 
DISCUSSION 
Diabetes mellitus is a metabolic disorder 
characterized by hyperglycemia and alterations in 
carbohydrate, fat and protein metabolism, associated with the 
continuous destruction of β-cell leads to the disturbance in 
glucose homeostasis. Liver and pancreas are the two main 
organs which plays important role in maintain the level by 
regulating alternative pathways between glucose uptake and 
gluconeogenesis (Ferre et al., 1996).Diabetes is induced by 
Alloxan (ALLOXAN) in animal model.  
 Currently available drugs for the treatment of 
Diabetes mellitus have a number of limitations, such as adverse 
effects and a high rate of secondary failure Although there isa 
growing trend towards using natural remedies adjunct to 
conventional therapy, traditionally used plants might provide a 
useful source of new hypoglycemic compounds. Although 
Butea Monosperma may be described as a medicinal plant used 
for various purposes, no scientific reports exist on its 
antihyperglycaemic effect. 
ALLOXAN is known to induce diabetes in animal 
models along with hyperlipidemia/atherosclerosis, diabetic 
nephropathy, retinopathy, and neuropathy. ALLOXAN 
mediated toxicity is might be due to their proposed site of 
action at nuclear DNA. The decomposition of ALLOXAN leads to 
formation of highly reactive carbonium ions, which cause 
DNAbases alkylation and also damage pancreatic-cell 
membrane and break the DNA strand which guide to the 
activation of poly (ADPribose) synthetase and NAD depletion, 
which ultimately leads to cell death (Portha et al., 1989). It has 
been previously reported that ALLOXAN selectively destroy 
the pancreatic cells that secrete insulin and results in 
substantial hyperglycemia as well as also result in weight loss, 
ketosis and a high rate of mortality (Arulmozhi et al., 2004, 
Szkudelski, 2001). 
 The present work was designed to investigate 
theantihyperglycaemic effects of Aqueous extract of Butea 
Monosperma (AEBM) extract inAlloxan diabetic albino rats. 
Butea monosperma is having the antioxidant properties it 
might be responsible for the antidiabetic activity. 
CONCLUSION 
Butea monosperma possess various pharmacological 
activities such as Diabetes Mellitus, Tonic, Jaundice, Diuretic, 
Scabies, Gonorrhea, and Antioxidant.  
In the present study, aqueous extract of Butea 
monospermashowed a promising anti diabetic effect in Alloxan 
and high fat diet induced diabetes in rats. Hence oral 
administration of Aqueous extract ofButea monosperma has 
the potential of antidiabetic activity. Further the active 
principles of Butea monosperma responsible for this property 
is too isolated Phytochemically and studies with these purified 
constitutions are waiting to understand the complete 
mechanism of anxiety activity. 
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